The Front Room — a clinical regulatory commons
RSS
← Back to feed

Linzess cleared for pediatric functional constipation

Sponsor
Ironwood Pharmaceuticals $IRWD
Drug
Linzess · linaclotide
Indication
Functional constipation
More on Ironwood Pharmaceuticals Google News

FDA approved Linzess (linaclotide) for pediatric patients aged 2+ with functional constipation.

What this means

Linzess is a capsule that helps relieve constipation by increasing fluid in the intestines and speeding up bowel movements. FDA has now approved Linzess for children aged 2 and older who have functional constipation, a condition where bowel movements are infrequent or difficult without a clear cause. This decision gives pediatricians and families a new treatment option, though parents should watch for signs of dehydration, a known risk in children taking the drug.

Read original at accessdata.fda.gov
Topic pediatric GI